Rhon-klinikum Ag · XETR:RHK
Rhon-klinikum — Q1 2016 Earnings Presentation
11 slides from Rhon-klinikum's earnings presentation, May 6, 2016
Slide 1: RHÖN-KLINIKUM AG First Quarter 2016 Results
RHÖN-KLINIKUM AG First Quarter 2016 Results May 6, 2015 Jens-Peter Neumann, CFO Dr. Kai G. Klinger
Slide 2: Disclaimer
Disclaimer This document has been prepared by RHÖN-KLINIKUM AG (“RHÖN-KLINIKUM” or “the Company”) for information purposes only, solely for use during this presentation. It must be treated confidentially by attendees at such presentation and must not be distributed, passed on or otherwise disclosed.
Slide 3: Highlights of First Quarter 2016
Highlights of First Quarter 2016 A smooth start into FY 2016 .. Pure organic volume growth slightly below average for Q1 periods due to a seasonality shift +4.2% organic increase in inpatient and outpatient cases in Q1 to 191,730 including approx. +1% more DRG case mix points .. and some small struc
Slide 4: P&L Key Figures Q1 2016
P&L Key Figures Q1 2016 Performance* vs. Q1 with some tailwinds from external growth .. Q1 2016 in € millions Q1 2015 +2.9% from first-time consolidation of “Kreisklinik”, comparison of organic revenue growth in Q1 distorted Revenue 291.5 100.0% +5.6% by minor structural effect Personnel exp. -187.8
Slide 5: Q1 2016 Core Balance Sheet Figures
Q1 2016 Core Balance Sheet Figures €1,516m €1,516m €890m Equity ratio 58.7% Non-current assets €1,159m 76.5% Equity €10m cash 41.3% €626m €37m Current assets Non-current liabilities 2.4% €10m financial debt €320m €358m cash 21.1% Current liabilities Assets Equity & liabilities Solid balance sheet wi
Slide 6: Dividend Proposal for 2016 AGM
Dividend Proposal for 2016 AGM The management board and supervisory board will propose to the Annual General Meeting on 9 June 2016 the distribution of a dividend of €0.80 per share (total dividend sum of €53.6m based on 66.96m shares) “Comprehensive participation by shareholders in the company’s su
Slide 7: Outlook FY 2016
Outlook FY 2016 Key levers Organic revenue growth +3 to +4% (volumes +1 to +2%; DRG prices approx. +2.6%; approx. -1% discount from volume freeze, +2,9% from Kreisklinik) Input prices: wages +2.5 to +3%; material costs +1.5 to +2% Positive and negative one-time effects in low to mid double-digit mil
Slide 8: Appendix – Financial Calendar
Appendix – Financial Calendar FY 2016 February 26, 2016 Preliminary results for financial year 2015 April 15, 2016 Press conference: publication of annual financial report 2015 May 6, 2016 Publication of interim report for the quarter ending March 31, 2016 June 8, 2016 Annual General Meeting (Jahrhu
Slide 9: Appendix – Price Regulation at a Glance
Appendix – Price Regulation at a Glance Average base rate increase in states with RHÖN hospitals Federal Total hospital system budget (weighted by RHÖN case mix) Level Wage sum increase as main reference number for RHÖN effective base rate Benchmark (wage sum) Layer 1 DRG inflation in 2016: +2.95 (2
Slide 10: Appendix – Shareholder Base
Appendix – Shareholder Base Like-for-like shareholder structure after capital reduction in 2015 as of 31 December 2015, according to the most recent notifications of voting rights at that time 19.8%2) B. Braun 50.30% 49.70% 47.1%1) Strategic Free Float Investors 17.6% Asklepios 6.9%2) Eugen Münch 3.
Slide 11: Breakdown of Main Extraordinary Effects on FY 2016 EBITDA
Appendix – Breakdown of Main Extraordinary Effects on FY 2016 EBITDA 155m to 2016 will still be influenced by compensatory one-off items 165m A > +35m lapse of contractual risk from Fresenius/Helios SPA and mandatory release of underlying reserves B > -8m cost burden due to deferred settlement of UK